Plough I have to agree. SBP with a now probable strong contender in the RCC market and about to demonstrate its efficacy in the USA. A market cap of $15M.
"There are approximately 30,000 new estimated cases of renal cell carcinoma per year in the USA
The total market size in the USA in the range of $2 billion dollar "
http://ott.od.nih.gov/db/abstxt.asp?refno=1339
There is no cure
You do the math.
SBP
solbec pharmaceuticals limited
